Oxford scientists develop calculator for statin side effect risk
Translated from German, summarized and contextualized by DistantNews.
At a glance
- Oxford University scientists developed a calculator to estimate individual risk of severe muscle damage from statin treatment.
- The tool analyzes 22 health factors using data from over 5.6 million Britons, finding less than 2% of patients face high risk.
- Researchers aim to reassure patients and encourage the over 60% who don't take statins despite recommendations to consider treatment.
Scientists at Oxford University have created a groundbreaking calculator designed to assess the individual risk of severe muscle disorders for patients undergoing statin therapy. Statins, widely prescribed to lower cholesterol levels and reduce the risk of heart attack and stroke, are often avoided by individuals due to concerns about side effects, particularly muscle pain.
The newly developed tool analyzes 22 routinely collected health indicators, including age, sex, ethnicity, body mass index, smoking status, existing medical conditions, vitamin D levels, and other medications. It utilizes anonymized medical data from over 5.6 million individuals in the UK to estimate the probability of serious muscle problems occurring within one, five, or ten years.
Published in "The Lancet Digital Health," the research indicates that over 98% of patients who are candidates for statin treatment have a very low risk of experiencing severe muscle complications. The researchers emphasize that this refers to serious issues leading to hospitalization or death, distinguishing them from milder muscle aches that some patients report. They suggest that many of these milder symptoms may not be directly caused by statins but could be related to factors like age, physical exertion, or even anxiety about side effects.
This finding is expected to alleviate concerns among many patients, as the study revealed that the actual risk of severe adverse effects is significantly lower than often perceived. The researchers also highlighted a substantial gap in lipid disorder management, noting that over 60% of individuals eligible for statins, including those at high risk for cardiovascular events, do not adhere to their prescribed treatment. They believe the new calculator could help bridge this gap by providing a clearer, personalized risk-benefit assessment, potentially encouraging more patients to accept and continue statin therapy.
Originally published by Der Standard in German. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.